264 related articles for article (PubMed ID: 30893872)
21. Tyrosine 394 is phosphorylated in Alzheimer's paired helical filament tau and in fetal tau with c-Abl as the candidate tyrosine kinase.
Derkinderen P; Scales TM; Hanger DP; Leung KY; Byers HL; Ward MA; Lenz C; Price C; Bird IN; Perera T; Kellie S; Williamson R; Noble W; Van Etten RA; Leroy K; Brion JP; Reynolds CH; Anderton BH
J Neurosci; 2005 Jul; 25(28):6584-93. PubMed ID: 16014719
[TBL] [Abstract][Full Text] [Related]
22. Structure-Based Drug Designing Recommends HDAC6 Inhibitors To Attenuate Microtubule-Associated Tau-Pathogenesis.
Zeb A; Park C; Rampogu S; Son M; Lee G; Lee KW
ACS Chem Neurosci; 2019 Mar; 10(3):1326-1335. PubMed ID: 30407786
[TBL] [Abstract][Full Text] [Related]
23. An identification of MARK inhibitors using high throughput MALDI-TOF mass spectrometry.
Hruba L; Polishchuk P; Das V; Hajduch M; Dzubak P
Biomed Pharmacother; 2022 Feb; 146():112549. PubMed ID: 34923338
[TBL] [Abstract][Full Text] [Related]
24. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons.
Padmanabhan J; Levy M; Dickson DW; Potter H
Brain; 2006 Nov; 129(Pt 11):3020-34. PubMed ID: 16987932
[TBL] [Abstract][Full Text] [Related]
25. Ser
Sandhu P; Naeem MM; Lu C; Kumarathasan P; Gomes J; Basak A
Bioorg Med Chem Lett; 2017 Feb; 27(3):642-652. PubMed ID: 27989667
[TBL] [Abstract][Full Text] [Related]
26. Tau pathology in Alzheimer disease and other tauopathies.
Iqbal K; Alonso Adel C; Chen S; Chohan MO; El-Akkad E; Gong CX; Khatoon S; Li B; Liu F; Rahman A; Tanimukai H; Grundke-Iqbal I
Biochim Biophys Acta; 2005 Jan; 1739(2-3):198-210. PubMed ID: 15615638
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of pyrazolopyrimidine derivatives as microtubule affinity regulating kinase 4 inhibitors: Towards therapeutic management of Alzheimer's disease.
Naqvi AAT; Jairajpuri DS; Noman OMA; Hussain A; Islam A; Ahmad F; Alajmi MF; Hassan MI
J Biomol Struct Dyn; 2020 Aug; 38(13):3892-3907. PubMed ID: 31512980
[TBL] [Abstract][Full Text] [Related]
28. Neighbored phosphorylation sites as PHF-tau specific markers in Alzheimer's disease.
Singer D; Lehmann J; Hanisch K; Härtig W; Hoffmann R
Biochem Biophys Res Commun; 2006 Aug; 346(3):819-28. PubMed ID: 16781671
[TBL] [Abstract][Full Text] [Related]
29. Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments.
Schneider A; Biernat J; von Bergen M; Mandelkow E; Mandelkow EM
Biochemistry; 1999 Mar; 38(12):3549-58. PubMed ID: 10090741
[TBL] [Abstract][Full Text] [Related]
30. Oxidized and phosphorylated synthetic peptides corresponding to the second and third tubulin-binding repeats of the tau protein reveal structural features of paired helical filament assembly.
Hoffmann R; Dawson NF; Wade JD; Otvös L
J Pept Res; 1997 Aug; 50(2):132-42. PubMed ID: 9273897
[TBL] [Abstract][Full Text] [Related]
31. MARKing tau for tangles and toxicity.
Drewes G
Trends Biochem Sci; 2004 Oct; 29(10):548-55. PubMed ID: 15450610
[TBL] [Abstract][Full Text] [Related]
32. Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules.
Alonso AC; Grundke-Iqbal I; Iqbal K
Nat Med; 1996 Jul; 2(7):783-7. PubMed ID: 8673924
[TBL] [Abstract][Full Text] [Related]
33. New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry.
Hanger DP; Betts JC; Loviny TL; Blackstock WP; Anderton BH
J Neurochem; 1998 Dec; 71(6):2465-76. PubMed ID: 9832145
[TBL] [Abstract][Full Text] [Related]
34. Receptor-based pharmacophore modeling, virtual screening, and molecular docking studies for the discovery of novel GSK-3β inhibitors.
El Kerdawy AM; Osman AA; Zaater MA
J Mol Model; 2019 May; 25(6):171. PubMed ID: 31129879
[TBL] [Abstract][Full Text] [Related]
35. Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration.
Wang JZ; Xia YY; Grundke-Iqbal I; Iqbal K
J Alzheimers Dis; 2013; 33 Suppl 1():S123-39. PubMed ID: 22710920
[TBL] [Abstract][Full Text] [Related]
36. A new TAO kinase inhibitor reduces tau phosphorylation at sites associated with neurodegeneration in human tauopathies.
Giacomini C; Koo CY; Yankova N; Tavares IA; Wray S; Noble W; Hanger DP; Morris JDH
Acta Neuropathol Commun; 2018 May; 6(1):37. PubMed ID: 29730992
[TBL] [Abstract][Full Text] [Related]
37. E-pharmacophore-based virtual screening to identify GSK-3β inhibitors.
Natarajan P; Priyadarshini V; Pradhan D; Manne M; Swargam S; Kanipakam H; Bhuma V; Amineni U
J Recept Signal Transduct Res; 2016 Oct; 36(5):445-58. PubMed ID: 27305963
[TBL] [Abstract][Full Text] [Related]
38. Kororamides, Convolutamines, and Indole Derivatives as Possible Tau and Dual-Specificity Kinase Inhibitors for Alzheimer's Disease: A Computational Study.
Llorach-Pares L; Nonell-Canals A; Avila C; Sanchez-Martinez M
Mar Drugs; 2018 Oct; 16(10):. PubMed ID: 30332805
[TBL] [Abstract][Full Text] [Related]
39. O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease.
Liu F; Iqbal K; Grundke-Iqbal I; Hart GW; Gong CX
Proc Natl Acad Sci U S A; 2004 Jul; 101(29):10804-9. PubMed ID: 15249677
[TBL] [Abstract][Full Text] [Related]
40. A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
Coutadeur S; Benyamine H; Delalonde L; de Oliveira C; Leblond B; Foucourt A; Besson T; Casagrande AS; Taverne T; Girard A; Pando MP; Désiré L
J Neurochem; 2015 May; 133(3):440-51. PubMed ID: 25556849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
